With extensive R&D experience, we will develop technologies and products that meet market needs.

Hello.
This is Sungwook Yang, CEO of XENOHELIX.
During my time at the University of Copenhagen in Denmark, I was deeply shocked by the sudden passing of colleagues, which made me realize the critical importance of early disease detection even in one of the world’s most advanced welfare states. This realization led me to further immerse myself in research on disease detection and new technologies. Based on these experiences and research, I founded the company in 2019.

While developing technologies for disease diagnosis, we have conducted fundamental research not only on detecting biomarkers but also on efficiently extracting nucleic acids from various sample types, in order to develop diagnostic products based entirely on our own technology.

Based on these core technologies, we have developed molecular diagnostic products for diseases such as fatty liver, and have also commercialized new biomaterials for skin care, including natural exosomes and miPDRN.

Great products create the highest value for customers and the market. XENOHELIX will continue to strive to grow into a globally recognized biotech company loved by all through the creation of such value.

XENOHELIX CEO Sungwook Yang